Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in Metastatic Thyroid Cancer
NCT00104871Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2004
- Primary completion
- May 2010
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in papillary thyroid cancer (PTC), follicular thyroid cancer (FTC), sponsored by National Cancer Institute. Started Dec 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
papillary thyroid cancer (PTC)follicular thyroid cancer (FTC)
Beyond the preview
Go deeper on NCT00104871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00104871.